Insulet PODD R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Insulet's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Insulet's R&D?
- Insulet (PODD) reported R&D of $89.7M in Q1 2026.
- How has Insulet's R&D changed year-over-year?
- Insulet's R&D increased by 50.5% year-over-year, from $59.6M to $89.7M.
- What is the long-term trend for Insulet's R&D?
- Over 4 years (2021 to 2025), Insulet's R&D has grown at a 17.1% compound annual growth rate (CAGR), from $160.1M to $301.1M.
- What does R&D mean?
- Spending on the development of new products and the improvement of existing ones.
- How do you interpret R&D?
- Higher spending indicates a focus on long-term innovation, though it reduces short-term earnings.
- How does R&D compare across companies?
- High R&D spend is standard for growth-stage medical device companies to maintain a competitive pipeline.